Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 842

1.

Patient comorbidity is associated with conservative treatment of localized prostate cancer.

Jespersen CG, Nørgaard M, Jacobsen JB, Borre M.

Scand J Urol. 2015 Apr 22:1-5. [Epub ahead of print]

PMID:
25903072
2.

Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.

Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P.

Eur Urol. 2015 Jul;68(1):53-8. doi: 10.1016/j.eururo.2014.12.026. Epub 2015 Mar 23.

3.

Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis.

Wallis CJ, Herschorn S, Saskin R, Su J, Klotz LH, Chang M, Kulkarni GS, Lee Y, Kodama RT, Narod SA, Nam RK.

Urology. 2015 Mar;85(3):621-7. doi: 10.1016/j.urology.2014.11.037.

PMID:
25733275
4.

Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong.

Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS, Ng CF.

Jpn J Clin Oncol. 2015 May;45(5):483-7. doi: 10.1093/jjco/hyv025. Epub 2015 Feb 26.

PMID:
25724216
5.

Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.

Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M, Gill IS.

J Urol. 2015 Aug;194(2):378-85. doi: 10.1016/j.juro.2015.02.084. Epub 2015 Feb 21.

PMID:
25711194
6.

Screening for cancer: when to stop?: A practical guide and review of the evidence.

Soung MC.

Med Clin North Am. 2015 Mar;99(2):249-62. doi: 10.1016/j.mcna.2014.11.002. Epub 2014 Dec 23. Review.

PMID:
25700582
7.

Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer.

Wallis CJ, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, Kulkarni GS, Lee Y, Kodama RT, Narod SA, Nam RK.

Br J Cancer. 2015 Mar 17;112(6):977-82. doi: 10.1038/bjc.2015.54.

PMID:
25688739
8.

Mortality in older men with low-risk prostate cancer and high comorbidity.

Stattin P.

J Clin Oncol. 2015 Mar 20;33(9):1086-7. doi: 10.1200/JCO.2014.58.2536. Epub 2015 Feb 2. No abstract available.

PMID:
25646191
9.

Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data for prediction of gastrointestinal toxicities in prostate cancer patients by using propensity score matched pair analysis.

Troeller A, Yan D, Marina O, Schulze D, Alber M, Parodi K, Belka C, Söhn M.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):435-43. doi: 10.1016/j.ijrobp.2014.09.046.

PMID:
25636766
10.

Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.

Berrington de Gonzalez A, Wong J, Kleinerman R, Kim C, Morton L, Bekelman JE.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):295-302. doi: 10.1016/j.ijrobp.2014.10.040.

11.

An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.

Daskivich TJ, Kwan L, Dash A, Saigal C, Litwin MS.

J Urol. 2015 Jul;194(1):73-8. doi: 10.1016/j.juro.2015.01.081. Epub 2015 Jan 23.

PMID:
25623745
12.

Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer.

Dolezel M, Odrazka K, Zouhar M, Vaculikova M, Sefrova J, Jansa J, Paluska P, Kohlova T, Vanasek J, Kovarik J.

Strahlenther Onkol. 2015 Apr;191(4):338-46. doi: 10.1007/s00066-014-0806-y. Epub 2015 Jan 15.

PMID:
25589224
13.

A systematic review of factors influencing older adults' decision to accept or decline cancer treatment.

Puts MT, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, Krzyzanowska M, Leighl NB, Springall E, Alibhai SM.

Cancer Treat Rev. 2015 Feb;41(2):197-215. doi: 10.1016/j.ctrv.2014.12.010. Epub 2014 Dec 26. Review.

14.
15.

The diffusion of docetaxel in patients with metastatic prostate cancer.

Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR.

J Natl Cancer Inst. 2014 Dec 24;107(2). pii: dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb.

PMID:
25540245
16.

Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study.

Lee SW, Jang HS, Lee JH, Kim SH, Yoon SC.

Medicine (Baltimore). 2014 Dec;93(28):e290. doi: 10.1097/MD.0000000000000290.

PMID:
25526468
17.

Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy.

Moses KA, Chen LY, Sjoberg DD, Bernstein M, Touijer KA.

BMC Urol. 2014 Dec 11;14:98. doi: 10.1186/1471-2490-14-98.

18.

Estimating preferences for treatments in patients with localized prostate cancer.

Ávila M, Becerra V, Guedea F, Suárez JF, Fernandez P, Macías V, Mariño A, Hervás A, Herruzo I, Ortiz MJ, Ponce de León J, Sancho G, Cunillera O, Pardo Y, Cots F, Ferrer M; Multicentric Spanish Group of Clinically Localized Prostate Cancer.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):277-87. doi: 10.1016/j.ijrobp.2014.09.044. Epub 2014 Dec 6.

PMID:
25491504
19.

Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy.

Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Resnick MJ, Barocas DA, Penson DF.

J Urol. 2015 Apr;193(4):1226-31. doi: 10.1016/j.juro.2014.11.006. Epub 2014 Nov 11.

PMID:
25451829
20.

Prognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer.

Koo KC, Yoo H, Kim KH, Park SU, Han KS, Rha KH, Hong SJ, Yang SC, Chung BH.

J Urol. 2015 Apr;193(4):1239-44. doi: 10.1016/j.juro.2014.10.088. Epub 2014 Oct 23.

PMID:
25444987
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk